Physician profile
William B Clark
NPI 1235202599
$6,094.37
in general payments reported to CMS, 2019-2025
33 companies · $712 in 2025
The $712 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $351 · 2021: $826 · 2022: $1,307 · 2023: $924 · 2024: $1,132 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.92 |
| Education | $190.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,701.16 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $776.13 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $397.43 | 2019 | |
| Myovant Sciences INC. | $304.96 | 2021-2022 | |
| Avion Pharmaceuticals | $302.49 | 2020-2022 | |
| Novo Nordisk INC | $298.57 | 2019-2025 | Wegovy |
| Coopersurgical, INC. | $281.07 | 2019-2025 | Paragard T 380a, Paragard T 380a, Mara Console |
| Sumitomo Pharma America, INC. | $267.64 | 2023-2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $238.30 | 2021-2025 | |
| Exeltis, USA INC. | $220.13 | 2020-2025 | Slynd |
| Pfizer INC. | $196.83 | 2019-2023 | |
| Shield Therapeutics INC | $149.07 | 2024-2025 | |
| Therapeuticsmd, INC. | $96.75 | 2019-2022 | |
| Hologic Sales and Service, LLC | $93.50 | 2019-2023 | Aptima |
| Organon LLC | $75.43 | 2022-2025 | Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.16 | 2023-2025 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $68.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Millicent US INC | $67.24 | 2019-2025 | Femlyv |
| Lupin INC. | $63.89 | 2019 | |
| Lilly USA, LLC | $56.99 | 2025 | Zepbound, Mounjaro |
| Mylan Pharmaceuticals INC. | $52.23 | 2021 | |
| Heron Therapeutics, INC. | $45.63 | 2023 | Zynrelef |
| Bayer Healthcare Pharmaceuticals INC. | $41.36 | 2019-2025 | |
| Daiichi Sankyo INC. | $34.32 | 2024 | Injectafer |
| Boston Scientific Corporation | $28.89 | 2019 | |
| Agile Therapeutics, INC. | $27.96 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $27.93 | 2019 | |
| Allergan, INC. | $26.31 | 2020 | |
| Ethicon US, LLC | $21.62 | 2022 | |
| Seqirus USA INC | $18.81 | 2024 | Flucelvax, Fluad |
| Gilead Sciences, INC. | $14.43 | 2019 | |
| Medicem INC. | $14.00 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.